title: Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis.
abstract: OBJECTIVE
  To conduct a meta-analysis of the studies assessing the effects of mifepristone on the uterus, uterine leiomyoma, and leiomyoma-related symptoms in premenopausal women.
  
  
  METHODS
  Meta-analysis.
  
  
  METHODS
  Centers for reproductive care.
  
  
  METHODS
  Premenopausal women who suffered from leiomyoma.
  
  
  METHODS
  We identified all of the studies published before December 2012 that compared the status of patients with leiomyoma before and after treatment with mifepristone.
  
  
  METHODS
  Leiomyoma-related symptoms, uterine or leiomyoma volume, changes in endometrial thickness.
  
  
  RESULTS
  A meta-analytic technique was used to study 11 randomized controlled trials involving 780 women with symptomatic uterine leiomyomas. The subjects received 2.5-25 mg/d of mifepristone for 3-6 months. Mifepristone could effectively reduce uterine and leiomyoma volume and alleviate leiomyoma symptoms, including hypermenorrhea, the mean menstrual blood loss, pelvic pain, pelvic pressure, anemia, and dysmenorrhea. There was no significant difference in the rate of atypical endometrial hyperplasia between the mifepristone treatment group and the placebo group.
  
  
  CONCLUSIONS
  Mifepristone significantly reduced uterine and leiomyoma volume and alleviated leiomyoma-related symptoms. We recommend 2.5 mg of mifepristone administered daily for 3 or 6 months as the optimum clinical treatment for leiomyoma. There is insufficient evidence that mifepristone treatment led to atypical endometrial hyperplasia.
authors.affiliation: Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Shen
authors.forename: Ying
authors.initials: Y
authors.lastname: Hua
authors.forename: Wenxiao
authors.initials: W
authors.lastname: Jiang
authors.forename: Wenwen
authors.initials: W
authors.lastname: Zhang
authors.forename: Miaomiao
authors.initials: M
authors.lastname: Chen
authors.forename: Xueqiong
authors.initials: X
authors.lastname: Zhu
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D015994:Incidence; D007889:Leiomyoma / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D015735:Mifepristone / Q000627:therapeutic use*; D017697:Premenopause; D012307:Risk Factors; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D015735:Mifepristone
keywords: Mifepristone; leiomyoma; meta-analysis